Description

Clindamycin & Clotrimazole Vaginal Tablets (100 mg / 200 mg)

Healthy Inc is a specialized global supplier and exporter of advanced gynecology, infectious disease, and targeted antimicrobial therapeutics. We provide ultra-high-purity, kinetically optimized Clindamycin & Clotrimazole Vaginal Tablets (100 mg / 200 mg), manufactured in WHO–GMP certified, high-precision specialized gynecological dosage facilities. This “Broad-Spectrum Antibacterial & Antifungal FDC” is a massive-volume, highly strategic export to maternity hospitals, gynecology networks, reproductive health clinics, and government health ministries in LATAM, the CIS, Africa, and Southeast Asia, serving as the globally mandated, first-line intervention for Mixed Vaginal Infections, Bacterial Vaginosis, and Vulvovaginal Candidiasis.

Product Overview

This highly advanced formulation operates as a coordinated, two-front biochemical assault on pelvic infections. It eliminates the need for complex diagnostic testing by providing a “blanket” cure that destroys both the aggressive bacteria and the resilient fungal spores simultaneously.

The “Syndromic Management & Dual-Pathogen” Specialist:

• Mechanism 1 (The Bacterial Ribosomal Blockade – Clindamycin): Clindamycin is a potent lincosamide antibiotic. It binds aggressively to the 50S subunit of the bacterial ribosome, physically halting the synthesis of essential proteins. This violently suppresses the growth of Gardnerella vaginalis, Mobiluncus, and Mycoplasma hominis, the primary drivers of foul-smelling Bacterial Vaginosis (BV).
• Mechanism 2 (The Fungal Cell Wall Collapse – Clotrimazole): Clotrimazole is a high-affinity imidazole antifungal. It selectively inhibits the enzyme lanosterol 14-α-demethylase, which is mandatory for the synthesis of ergosterol (the “skeleton” of the fungal cell membrane). Without ergosterol, the fungal cell wall becomes porous and leaks its internal contents, leading to the rapid death of Candida albicans (the cause of yeast infections).
• Mechanism 3 (The V-Tab Kinetic Advantage): Unlike oral antibiotics that must travel through the entire bloodstream (causing nausea and diarrhea), these Vaginal Tablets deliver 100% of the active payload directly to the site of infection. This “Localized High-Concentration” protocol ensures 99% eradication of pathogens within 3 to 7 days with zero systemic side effects.

Product Composition & Strength

We supply this product as a Precision-Blended, Non-Greasy Vaginal Tablet (V-Tab), packed exclusively in highly secure, moisture-resistant Alu-Alu or Alu-PVC blister strips, often accompanied by a specialized applicator for sterile insertion.

*Pack Sizes: 3-Tablet or 7-Tablet Strips (Optimized specifically for the strict, short-course clinical curative regimens).

Technical & Logistics Specifications

Critical data for Pharmaceutical Importers, Gynecology Distributors, and Hospital Procurement Boards.

Manufacturing Authority

Marketed and Distributed by Healthy Inc from WHO-GMP & ISO 9001:2015 certified units.

• Vaginal Dispersion & Heat Stability (CRITICAL COMPLIANCE): The engineering challenge here is balancing “Stability” vs. “Dissolution.” Standard suppositories often melt in the shipping container during transport to hot climates (Africa/SE Asia). Our V-Tabs utilize a specialized dry-compression matrix that remains rock-solid up to 40°C on the shelf, but shatters and disperses within 5 minutes of insertion. We guarantee global procurement boards a product that maintains 100% therapeutic potency from the factory to the patient.

Therapeutic Indications (Human Use)

Indicated for the targeted, rapid management of complex gynecological infections:

• Mixed Vaginal Infections: Simultaneous treatment of bacterial vaginosis and vulvovaginal candidiasis (yeast).
• Bacterial Vaginosis (BV): Symptomatic relief of abnormal discharge, fishy odor, and irritation.
• Infectious Leukorrhea: Management of excessive white/yellow vaginal discharge caused by infectious pathogens.

Dosage & Administration

Recommended Dosage (Strictly as per Gynecologist Guidelines):

• The Short-Course Protocol: 1 tablet (V-Tab) to be inserted deeply into the vagina, preferably at bedtime, for 3 to 7 consecutive days.
• Administration: STRICTLY NOT FOR ORAL USE. Must be inserted using the provided applicator or a clean finger.
• Menstruation Rule: Treatment should not be performed during menstruation to prevent the medication from being washed away by menstrual flow.

Safety Warnings (CRITICAL Regulatory & Clinical Data):

• Condom/Diaphragm Failure (FATAL FOR PROTECTION): The base of vaginal tablets can physically degrade the latex in condoms and diaphragms, rendering them useless as contraceptives or STI protection. Patients MUST use alternative protection during and for 72 hours after therapy.
• Local Irritation: May cause transient vaginal burning, itching, or redness during the first dose as the infection is being cleared.
• Pregnancy Caution: Use during the first trimester only if absolutely necessary. During the second and third trimesters, the tablet should be inserted manually (without the applicator) to avoid cervical trauma.

Global Export & Contract Manufacturing Services

Healthy Inc stands as a premier Pharmaceutical Exporter in India, dedicated to serving international Pharma Traders, Wholesalers, and Maternal Health Networks. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) services for Advanced Gynecological FDCs, Vaginal Tablets, and Syndromic Anti-infectives. Whether you are looking for a reliable Government Tender Supplier for maternal health programs in Africa or a B2B Pharma Marketplace partner for the CIS, our highly regulated logistics network ensures timely, secure delivery of WHO-GMP certified products.